The INTACS® and INTACS® SK (severe keratoconus) intra-corneal rings and the Cross-Linking by Iontophoresis procedure offer major benefits in the treatment of this rare disease.
Keratoconus corresponds to a deformation of the cornea which tapers gradually and takes the shape of an irregular cone. This rare eye disease, usually occurring in late adolescence, creates significant vision problems: progressive loss of visual acuity (blurred or distorted vision), accompanied by myopia and astigmatism. This disease, which affects one in 2,000 people, is often detected during puberty. After wearing glasses and special lenses, corneal transplantation or implantation of intra-corneal rings is essential in one out 10 individuals (source), to allow the patient to recover a normal quality of life and satisfactory visual comfort. In parallel, Cross-Linking can be performed for progressive keratoconus in order to prevent the disease from worsening.
The use of alternatives to corneal transplantation, such as intra-corneal rings and Cross-Linking, helps to offset the shortage of grafts and the risk of rejection (of 4,372 cornea transplants in 2012, 17% were performed to treat keratoconus (source)).
With its new Hi-Tech Division, the Horus Pharma laboratory is especially committed to continuously improving patient care by offering a range of products for treatment of keratoconus and related visual disturbances. This range offers two advanced devices: a complete Cross-Linking platform and INTACS® and INTACS® SK intra-corneal rings.
The Cross-Linking by Iontophoresis procedure
Unlike conventional procedures, Iontophoresis is faster, simpler, more convenient for the practitioner and provides greater confort to the patient.
This non-invasive technique consists of penetrating the riboflavin molecules through the epithelium under the effect of a low intensity electric field. After the impregnation phase, riboflavin contained in Ricrolin+® is polymerized using the Vega lamp 10mW. This new procedure takes only 14 minutes compared to an hour with the conventional procedure and reduces the risk of complications by avoiding removal of the epithelium.
All new products associated with Iontophoresis are medical devices that are CE marked and in compliance with European health and safety standards.
INTACS® and INTACS® SK intra-corneal implants
The purpose of the implant is to increase the thickness of the cornea at the periphery. In patients with keratoconus, implants modify the corneal curvature to reduce myopia or astigmatism. It is possible to implant segments of different thicknesses according to the position of the cone and the myopia dioptres and astigmatism in need of correction. Furthermore, INTACS® and INTACS® SK have the advantage of being positioned in an optical zone avoiding any undesirable visual effects such as halo formation.
Developed by the company AJL, in Victoria (Spain), INTACS® and INTACS® SK intra-corneal implants are sold in France exclusively by Horus Pharma laboratories. With this agreement, Horus Pharma laboratories solidifies their expertise in treatment of keratoconus. The INTACS® implants (7mm) and INTACS® SK (6mm) also enhance the company’s Hi-Tech offering, which also notably includes a complete Cross-Linking platform.